Pages that link to "Q61910691"

The following pages link to Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism (Q61910691):

Displaying 30 items.

• Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models (Q26764739) (← links)
• Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin (Q33613354) (← links)
• Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors. (Q33628703) (← links)
• Prediction of the Intestinal First-pass Metabolism of CYP3A and UGT Substrates in Humans from in vitro Data (Q34006083) (← links)
• Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. (Q34476096) (← links)
• Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism (Q36099442) (← links)
• In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites (Q36105348) (← links)
• Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers (Q36406247) (← links)
• Biomedical Technologies for in vitro Screening and Controlled Delivery of Neuroactive Compounds (Q37010459) (← links)
• Population-based mechanistic prediction of oral drug absorption (Q37214520) (← links)
• Towards quantitative prediction of oral drug absorption (Q37265500) (← links)
• In vitroandin vivosmall intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences (Q37920916) (← links)
• Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. (Q39810440) (← links)
• Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: the role of TLR2 and NOD2. (Q40120821) (← links)
• Preparation and characterization of rodent intestinal microsomes: comparative assessment of two methods (Q41832624) (← links)
• Quantifying gut wall metabolism: methodology matters (Q42289931) (← links)
• Assessing circadian rhythms during prolonged midazolam infusion in the pediatric intensive care unit (PICU) children. (Q43632977) (← links)
• Mass spectrometry-based quantification of CYP enzymes to establish in vitro/in vivo scaling factors for intestinal and hepatic metabolism in beagle dog. (Q44958687) (← links)
• Predicting drug candidate victims of drug-drug interactions, using microdosing (Q45348533) (← links)
• Relative importance of intestinal and hepatic glucuronidation-impact on the prediction of drug clearance (Q46137927) (← links)
• Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine (Q46865623) (← links)
• Protein Abundance of Clinically Relevant Drug-Metabolizing Enzymes in the Human Liver and Intestine: A Comparative Analysis in Paired Tissue Specimens (Q47330563) (← links)
• Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers (Q47664709) (← links)
• A Physiologically Based Pharmacokinetic Model for Pregnant Women to Predict the Pharmacokinetics of Drugs Metabolized Via Several Enzymatic Pathways. (Q47963518) (← links)
• Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study (Q84472792) (← links)
• Differential regulation of intestinal and hepatic CYP3A by 1α,25-dihydroxyvitamin D3 : Effects on in vivo oral absorption and disposition of buspirone in rats (Q90403965) (← links)
• A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum (Q91588465) (← links)
• Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers (Q92454707) (← links)
• Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model (Q93016091) (← links)
• Characterization of Porcine Hepatic and Intestinal Drug Metabolizing CYP450: Comparison with Human Orthologues from A Quantitative, Activity and Selectivity Perspective (Q93024486) (← links)